GlassScriptPhysician profile
Richard S Gottfried
NPI 1023094323
$33,948.79
in general payments reported to CMS, 2019-2025
57 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,947 · 2020: $4,162 · 2021: $5,201 · 2022: $5,768 · 2023: $5,814 · 2024: $3,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,870.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,786.50 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $5,590.56 | 2019-2024 | Farxiga, Breztri, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,644.43 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $2,170.34 | 2019-2023 | Wegovy |
| Glaxosmithkline, LLC. | $1,901.46 | 2019-2024 | Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $1,528.79 | 2019-2022 | |
| Gilead Sciences, INC. | $1,303.23 | 2019-2023 | Epclusa |
| Teva Pharmaceuticals USA, INC. | $1,277.97 | 2019-2024 | Uzedy |
| Amgen INC. | $1,147.36 | 2019-2024 | Otezla, Repatha, Prolia |
| Esperion Therapeutics, INC. | $749.54 | 2020-2023 | Nexletol, Nexlizet |
| Pfizer INC. | $740.87 | 2019-2021 | |
| Allergan, INC. | $731.35 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $658.05 | 2019-2022 | |
| Lilly USA, LLC | $599.96 | 2019-2022 | |
| Eisai INC. | $523.08 | 2019-2024 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Gottfried listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.